• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DURECT Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    9/26/24 4:30:09 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    8-K
    0001082038false00010820382024-09-252024-09-25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    September 25, 2024

    Date of Report

    (Date of earliest event reported)

     

    DURECT CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Delaware

     

    000-31615

     

    94-3297098

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    10240 Bubb Road

    Cupertino, CA 95014

    (Address of principal executive offices) (Zip code)

    (408) 777-1417

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

    Trading Symbol

    Name of Each Exchange on Which Registered

    Common Stock $0.0001 par value per share

     

     

    DRRX

    The NASDAQ Stock Market LLC

    (The Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

     

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    At the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of DURECT Corporation (the “Company”), held online via live audio webcast on September 25, 2024, the Company’s stockholders approved an amendment and restatement of the Company’s 2000 Stock Plan (as amended and restated, the “Amended Stock Plan”) to increase the number of shares of the Company’s common stock available for issuance by 2,000,000 shares and to extend the term so that the Amended Stock Plan will terminate on the date that is ten years following stockholder approval of the Amended Stock Plan (i.e., September 25, 2034).

    A more complete summary of the material terms of the Amended Stock Plan is set forth in “Proposal No. 4 - Approval of the Amendment and Restatement of the 2000 Stock Plan” in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on August 12, 2024 (the “Proxy Statement”), which description is incorporated by reference herein. The summary in the Proxy Statement and above description of the amendment of the Amended Stock Plan do not purport to be complete and are qualified in their entirety by the full text of the Amended Stock Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting of the Company held online via live audio webcast on September 25, 2024, there were 22,163,186 shares represented to vote either in person or by proxy, or 71.4% of the outstanding shares, which represented a quorum. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting were as follows:

    Proposal 1: Election of Directors

    Mohammad Azab, James E. Brown and Gail M. Farfel were elected as Class III directors to serve until the 2027 annual meeting of stockholders of the Company or until their successors have been duly elected and qualified or, if sooner, until their earlier deaths, resignations, or removals. The voting for each director was as follows:

    For

    Withheld

    Broker Non-Votes

    Mohammad Azab

     

    6,505,722

     

    538,023

     

    15,119,441

    James E. Brown

     

    6,281,190

     

    762,555

     

    15,119,441

    Gail M. Farfel

     

    6,448,037

     

    595,708

     

    15,119,441

    Proposal 2: Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 350,000,000

    The Charter Amendment was approved based upon the following votes:

     

    For

    Against

    Abstain

    Broker Non-Votes

    19,164,468

    2,608,324

     390,394

    –

     

    Proposal 3: Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide for exculpation of officers to the extent permitted by the Delaware General Corporation Law

    The amendment to our Certificate of Incorporation to provide for exculpation of officers to the extent permitted by the Delaware General Corporation Law was not approved based upon the following votes:

    For

    Against

    Abstain

    Broker Non-Votes

    5,798,260

     

    1,176,929

     

    68,556

     

    15,119,441

     

    2


     

     

    Proposal 4: Approval of an amendment and restatement of the Company’s 2000 Stock Plan to increase the number of shares of the Company’s Common Stock available for issuance pursuant to the plan by 2,000,000 shares and to extend the plan’s term for ten years from the date of the 2024 Annual Meeting

     

    The Amended Stock Plan was approved based upon the following votes:

    For

    Against

    Abstain

    Broker Non-Votes

    5,794,670

     1,016,548

    232,527

     15,119,441

     

    Proposal 5: Say on Pay – A non-binding, advisory vote on the approval of executive compensation

    The compensation of the Company’s named executive officers was approved on a non-binding, advisory basis based upon the following votes:

    For

    Against

    Abstain

    Broker Non-Votes

    5,895,423

     

    913,798

     

    234,524

     

    15,119,441

     

    Proposal 6: Ratification of Appointment of the Independent Registered Public Accounting Firm for the Company for the Current Fiscal Year

    The appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for fiscal year 2024 was ratified based upon the following votes:

    For

    Against

    Abstain

    Broker Non-Votes

    21,429,526

    664,616

    69,044

    –

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

     

     

     

    Exhibit No.

     

    Description

    10.1

    DURECT Corporation 2000 Stock Plan, as amended

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

    3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    DURECT Corporation

     

     

     

     

     

    Date: September 26, 2024

     

    By:

     

    /s/ James E. Brown

     

     

     

     

        James E. Brown

        President and Chief Executive Officer

     

     

     

     

     

     

    4


    Get the next $DRRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    SEC Filings

    View All

    SEC Form 15-12G filed by DURECT Corporation

    15-12G - DURECT CORP (0001082038) (Filer)

    9/22/25 6:36:16 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by DURECT Corporation

    EFFECT - DURECT CORP (0001082038) (Filer)

    9/15/25 12:15:04 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by DURECT Corporation

    S-8 POS - DURECT CORP (0001082038) (Filer)

    9/11/25 11:14:47 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

    Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif., Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the second quarter ended June 30, 2025 and provided an update on the previously announced acquisition of DURECT by Bausch Health Companies Inc. (Bausch Health). Recent business highlights and updates: In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with Bausch Health America

    8/12/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

    Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

    5/13/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Durect with a new price target

    HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

    5/5/21 6:31:29 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Durect with a new price target

    Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    2/3/21 8:15:53 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by President & CEO Brown James E

    4/A - DURECT CORP (0001082038) (Issuer)

    9/16/25 2:16:30 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Robertson Judith J. closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 9:34:05 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Brown James E returned 96,959 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    9/12/25 8:47:03 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    3/27/24 3:15:14 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by DURECT Corporation

    SC 13G - DURECT CORP (0001082038) (Subject)

    2/16/24 4:09:22 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Financials

    Live finance-specific insights

    View All

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

    CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

    3/19/25 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

    -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

    11/13/24 4:01:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    View All

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Medicinal Chemicals and Botanical Products

    DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

    CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

    3/21/23 4:30:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

    CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

    7/5/22 8:30:00 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care